oxycodone controlled release / Generic mfg. - LARVOL DELTA

Considerations of Vertebrogenic Lower Back Pain After Basil-Vertebral Nerve Ablation (BVNA) Complicated in a Postmenopausal Woman (ASRA-FALL 2025) - "Background & Rationale Chronic Low Back Pain (CLBP) & Osteoporosis CLBP is a leading cause of disability in older adults Vertebral endplate pathologies, including Modic changes, are linked to persistent back pain BVNA is increasingly used for CLBP but remains relatively contraindicated in osteoporosis (T-score < –2.5) Knowledge Gap Few studies document Modic changes post-BVNA in osteoporotic patients High-risk populations (postmenopausal women, prior spinal surgery) require careful pre-procedural screening Considerations of Vertebrogenic Lower Back Pain After Basivertebral Nerve Ablation (BVNA) Complicated in a Postmenopausal Woman: Case Report Case Summary Patient Overview 63-year-old female with history of OSA, hypertension, GERD, IBS, osteoporosis, prior L3–S1 microdiscectomy Persistent postsurgical low back pain treated with L3–L5 medial branch RFA and L5–S1 BVNA Clinical Presentation Pain: stabbing, burning, tingling; worsened with flexion/extension;..."

Clinical • Back Pain • Cardiovascular • Gastroesophageal Reflux Disease • Hypertension • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology

From addiction to aggression: The spillover effects of opioid policies on intimate partner violence. (PubMed, J Health Econ) - "We investigate how a key supply-side intervention - the abuse-deterrent reformulation of a widely-diverted opioid, OxyContin - affected IPV...The reformulation reduced IPV only in states with smaller illicit drug markets, while states with larger illicit drug markets experienced increased heroin-involved IPV due to substitution towards illicit opioids. Our results underscore the importance of identifying populations at high risk of substitution to illicit opioids and moderating this risk with evidence-based policies."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Substance Abuse

No-PAIN: NSAID Use After Robotic Partial Nephrectomy (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: University of Miami | Trial completion date: Sep 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Kidney Cancer • Oncology • Pain • Renal Cell Carcinoma • Solid Tumor

Accountability in global health systems: insights from a network analysis of Purdue Pharmaceuticals. (PubMed, Global Health) - "Beginning in 1996, Purdue Pharmaceuticals (Purdue) knowingly mislabeled and mass marketed OxyContin (oxycodone), an opioid painkiller, catalyzing the opioid crisis which has been responsible for more than 600 000 deaths in and beyond North America...Through this in-depth examination of the complex interactions involved in global health and pharmaceutical systems, this study offers a nuanced understanding of the diverse actors mobilized and the unique strengths leveraged within and by accountability networks. Further, in examining these networks' differences, interconnectedness, and peculiarities, we broaden the scope of how accountability is defined, conceptualized, and operationalized in global health systems."

Journal • Pain

Non-Narcotic Pain Control After ACL Reconstruction (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: The Cleveland Clinic | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Pain

Postmarketing Research for Opioid Abuse-Deterrent Formulations: A Narrative Review. (PubMed, J Pain Res) - "Currently, 4 opioid formulations carry the ADF designation: XTAMPZA® ER (oxycodone), OXYCONTIN® (oxycodone hydrochloride), HYSINGLA™ ER (hydrocodone bitartrate), and ROXYBOND™ (oxycodone hydrochloride). Of note, XTAMPZA ER has shown sustained lower levels of nonoral abuse or misuse compared with other ADFs, despite a substantial increase in dispensed prescriptions since its launch in 2016. Additional postmarketing research is needed, especially for HYSINGLA ER and ROXYBOND."

Journal • P4 data • Review • Pain

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (clinicaltrials.gov) - P2 | N=170 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jul 2026 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Oncology

From dealer to doctor: A case study examining how Purdue Pharma sought to leverage racial health disparities to attenuate flagging OxyContin sales. (PubMed, Soc Sci Med) - "We contextualize the results to underline the importance of processes of structural racism to segmenting the pain management and substance use treatment markets in a manner that sought to capitalize on the very racism that prevented Asian, Black, Indigenous and Latino patients from obtaining pharmaceutical relief in the earlier days of the epidemic. We conclude that, (1) in absence of stronger federal regulation, especially in light of the recent reversal of the Chevron doctrine, local and state regulatory policies have found considerable success in limiting pharmaceutical excess, and policy at subnational levels will continue to be essential as the opioid epidemic still rages; and (2) greater use of resources such as the opioid industry documents can provide novel insight into processes of structural racism and offer targets for counter-intervention strategies."

Journal • Pain

US reaches a final $7.4bn settlement on opioid oxycontin, cause of 850 000 deaths. (PubMed, BMJ) - No abstract available

Journal

Understanding the demographics of the opioid overdose death crisis. (PubMed, J Popul Econ) - "Additionally, I analyze the long-term impacts of OxyContin's launch, discovering that it induced substantial differences in overdose rates by sex and education...This research highlights how certain groups have been disproportionately affected by the opioid crisis and the foundational role of supply-side shocks to opioid access in explaining the demographics of the overdose death crisis. The online version contains supplementary material available at 10.1007/s00148-025-01108-0."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders

Epidemiology of Fentanyl Overdose: A Comprehensive Review (CPDD 2025) - "Financial Support : Substance Abuse Epidemiology Training Program (SAETP) at Columbia University T32DA031099 Aims: The first wave of the opioid epidemic began in the mid-1990s with the production and marketing of oxycontin. The surge in fentanyl-related deaths is exacerbated by polysubstance use, notably the combination of fentanyl with other substances like xylazine, elevating the risk of fatal outcomes. Significant increases in fentanyl-related overdose deaths have been observed among adolescents, young adults, and Black individuals. Fentanyl overdose deaths surged in Eastern states and were higher in urban areas."

Clinical • Review • Addiction (Opioid and Alcohol) • Substance Abuse

Non-Narcotic Pain Control After ACL Reconstruction (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: The Cleveland Clinic

New P3 trial • Pain

Pharmacological Perspective on the Neurobiology of PI3K-Akt-mTOR Signalling in Opioid Dependence. (PubMed, CNS Neurol Disord Drug Targets) - "These have effects identical to those of morphine and work by interacting with opioid receptors such as morphine, heroin, opium, buprenorphine, and Oxycontin. The review enlisted the clinical trials of different types of opioid addiction or dependence. The review offers a succinct summary of many studies that establish a correlation between the PI3K/Akt-mTOR signaling pathway and various receptors implicated in multiple forms of opioid-related dependency."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Tobacco Addiction

Validation studies and multiomics analysis of Zhx2 as a candidate quantitative trait gene underlying brain oxycodone metabolite (oxymorphone) levels and behavior. (PubMed, J Pharmacol Exp Ther) - "SIGNIFICANCE STATEMENT: This study validated Zhx2 as a gene whose dysfunction increases brain levels of a highly potent and addictive metabolite of oxycodone, oxymorphone, in a female-specific manner. This result has broad implications for understanding the role of oxycodone metabolism and brain oxymorphone levels in the addiction liability of oxycodone (the active ingredient in OxyContin) and highlights the need for the study of sex differences in opioid metabolism as it relates to the addiction liability of opioids and opioid use disorder."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Substance Abuse • ZHX2

Impact of oxycodone for the treatment of acute postoperative pain in cesarean section: A review. (PubMed, Medicine (Baltimore)) - "These included documents disputed oral oxycodone and patient-controlled intravenous analgesia (PCIA) morphine, compared oral oxycodone and intravenous morphine, investigated sustained-release oral oxycodone and intrathecal morphine, investigated slow release tapentadol and controlled-release oxycodone, investigated ketoprofen, combination of acetaminophen + oxycodone, acetaminophen, and placebo, evaluated oral oxycodone and epidural ropivacaine + sufentanil, evaluated oral oxycodone and PCIA piritramide, evaluated the combination oxycodone + acetaminophen and separately administered oxycodone/acetaminophen, compared the immediate-release oxycodone and controlled-release oxycodone, compared the oral and intravenous oxycodone, disputed PCIA oxycodone or morphine, compared epidural oxycodone and morphine, evaluated PCIA oxycodone, sufentanil or their combination. Oxycodone showed superior or similar postoperative analgesic efficacy compared with other opioids in various..."

Journal • Review • Pain

Postmortem Redistribution of Oxycodone. (PubMed, Drug Test Anal) - "On death scene investigation, two packs of 40 mg OxyContin extended release and one alprazolam blister were found...The analyses of specimens collected at two different times clearly demonstrate variation of blood OC concentrations with time. Postmortem redistribution from organs was also evidenced by high concentrations of OC in tissues such as the liver and kidney."

Journal

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jul 2024 ➔ Jul 2025

Enrollment closed • Trial primary completion date • Oncology

The Growth of Illicit Drug Use and Its Effects on Murder Rates. (PubMed, Health Econ) - "After reformulation, I find significantly greater relative increases in murder rates in states with high pre-reformulation rates of OxyContin misuse. The results support a causal link between the opioid epidemic and crime."

Journal • Addiction (Opioid and Alcohol)

Oxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural Human Immunodeficiency Virus Outbreak in US History. (PubMed, Pharmacoepidemiol Drug Saf) - "Opana ER rapidly supplanted OxyContin in a vulnerable population that was at heightened risk for HIV who subsequently faced an immediate supply shock after its reformulation. Pharmacy transactions are critical for suspicious order monitoring and pharmacovigilance by US and international agencies especially during deleterious supply shocks in legal and illicit drug markets."

Journal • Human Immunodeficiency Virus • Infectious Disease

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain (clinicaltrials.gov) - P2 | N=177 | Not yet recruiting | Sponsor: 3D Medicines | Phase classification: P2a/2b ➔ P2 | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Combination therapy • Phase classification • Trial completion date • Trial primary completion date • Oncology • Pain

Interconnected influence: Unraveling purdue pharmaceutical's role in the global response to the opioid crisis. (PubMed, Int J Drug Policy) - "This study advances understandings of the complex interplay between transnational pharmaceutical companies, global health systems, regulatory bodies, and public health. In doing so, we underscore the need for stronger regulation and increased transparency surrounding the interactions between pharma, patient groups, governments, and international organizations to better address and prevent future harms."

Journal • Pain

The devastating dance between opioid and housing crises: Evidence from OxyContin reformulation. (PubMed, J Health Econ) - "Finally, we find evidence of increased marital disruption post-reformulation. Our findings underscore the urgent need for collaborative efforts between public health and housing authorities to address both the opioid and housing crises."

Journal • Psychiatry

Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (clinicaltrials.gov) - P1 | N=84 | Completed | Sponsor: Ensysce Biosciences | Phase classification: P1b ➔ P1

Phase classification

Synthetic opioids in Poland-A cause for concern or a media distraction? (PubMed, Int J Drug Policy) - "Poland currently does not seem to be in a position that resembles an early stage of an opioid crisis. With this article we want to calm a heated public debate that is currently taking place in Poland, and redirect attention to a much more substantial problem of synthetic cathinones."

Journal

The Imperative of Regulation: The Co-creation of a Medical and Non-medical US Opioid Crisis. (PubMed, Psychoactives) - "In the past decade the sharpest increase in deaths occurred among those related to fentanyl and fentanyl analogs (illicitly manufactured, synthetic opioids of greater potency). In the first opioid crisis wave (1998-2010), opioid-related deaths were mainly associated with prescription opioids such as Oxycontin (oxycodone hydrochloride)...Ironically, this turned the most powerful geopolitical force in the war against drugs into its greatest victim. Due to formulary availability and regulatory barriers to accessibility European countries have been relatively protected against following suit the US opioid crisis."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Pain • Psychiatry